Dynasil Corp Of America · OTC:DYSL
Dynasil Corp Of America — Shareholder Meeting (February 2016)
30 slides from Dynasil Corp Of America's shareholder meeting presentation, Feb 25, 2016
Slide 1: Annual Meeting of Stockholders
Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick, Chairman, President and CEO February 25, 2016
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Forward - looking statements i
Slide 3: Corporate Objectives - Ongoing
3 Corporate Objectives - Ongoing 1. Continued growth in Optics revenue through organic growth and opportunistic acquisitions to replace loss of Dynasil Products’ revenue and lower Contract Research revenue. 2. Conversion of job shop revenue stream across the Optics companies to more predictable, lon
Slide 4: Financial Summary Fiscal Year 2015 vs. 2014
4 Financial Summary Fiscal Year 2015 vs. 2014 Revenue decreased from $42.3 million in fiscal 2014 to $ 40.5 million in 2015. • Optics revenue increased 11%, from $19.6 million to $21.8 million. • Contract Research revenue declined 15% from $21.9 million to $18.8 million • Instruments segment had no
Slide 5: Fiscal Year 2015 Performance Highlights
5 Fiscal Year 2015 Performance Highlights Record Revenue at Three Optics Operational Units Optometrics - Secured the L - 3 grating contract followed by capital and construction requirements to meet the L - 3 production demands. Complete realignment of production floor and relocation of the administr
Slide 6: Debt
Debt $14,000,000 $12,000,000 $10,000,000 $8,000,000 $6,000,000 $4,000,000 $2,000,000 $- myo Rare > > 2 oD Cars 2 2 2 © Sa Oe OO gS oP FF ZK GP KF oF VF i ——Santander ——=Middlesex =——=MCRC ——Optometrics Xcede — Total ~_» Dynasil ‘
Slide 7: Corporate Objectives - 2016
7 Corporate Objectives - 2016 1. Secure external funding of Xcede Technologies for ongoing development of the tissue sealant technology. 2. Yield improvements across our Optics companies. 3. Continued commercial revenue growth in the double digit range. 4. Maintenance of 18+ month backlog in our res
Slide 8: Fiscal Year 2016 1st Quarter Financial Summary
8 Fiscal Year 2016 1 st Quarter Financial Summary First quarter fiscal 2016 r evenue grew to $11.2 million from $9.6 million in the 1 st quarter of fiscal 2015: • Contract Research revenue increased by 7% to $5.0 million. • Optics revenue increased by 26% to $6.2 million as a result of internal reve
Slide 9: 1st Quarter Fiscal 2016 – Performance Highlights
9 1 st Quarter Fiscal 2016 – Performance Highlights • Optics revenue of $6.2 million, RMD revenue at $5.0 million • Increased array shipments at Hilger • Development of Hybrid Filter product line at Optometrics launched at Photonics West • Completion of Xcede/Cook definitive agreement • Initiation o
Slide 10: RMD Highlights
RMD Highlights Dr. Kanai Shah February 2016
Slide 11: Fiscal Year 2015 Highlights
Fiscal Year 2015 Highlights 11 Closed fiscal year 2015 at $ 19.33 million , 1 st quarter f iscal 20 16 at $5.05 million B acklog of ~$31 million as of Feb 1, 2016 Continued push for larger projects & strategic bidding Launched 3” CLYC as a product, 3 instruments now use CLYC 5 Patents awar
Slide 12: Commercial Products
12 Commercial Products Thermo - Scientific T arget Systemelectronik INL Neutron Imaging System: Commercial Sale Zetec ECT Power Plant Probe 3” CLYC Crystals CLYC Pillars CLYC - SSPM Modules 1.5” SrI 2 :Eu
Slide 13: Crystals
Crystals 13 Thallium Elpasolites Scintillating Bolometers New Halide C ompositions InI Tl 6 SeI 4 LiInSe 2 11x11 TlBr Array
Slide 14: Plastics, Organic, and Ceramic Materials
14 Plastics, Organic, and Ceramic Materials Tin Loaded Plastics 4”x5”Neutron/Gamma P lastics > 1.5”x1.5”x1” Garnet Ceramics 4” DPA 12x12 Garnet Ceramic Array 2.6x2.6x20 mm3 pixels for PET Garnet Array read by 8x8 SiPM
Slide 15: Storage Phosphors, Films, Photocathodes, Photonic Crystals
15 Storage Phosphors K 2 CsSb Cs 3 Sb Photocathodes Films, Photocathodes , Photonic C rystals LNI & GdI 3 :Ce LuI 3 :Ce Photonic C rystals Lu 2 O 3 :Eu ALD Coatings for Night Vision
Slide 16: Sensors
16 Sensors Gammas (Plastic) Fast Neutrons (Plastic) Thermal Neutrons (CLYC) Gammas (CLYC) ALD Coated APD Composite Neutron Detector TlBr CFG Flexible ECT Sensor Array Wide Band Gap Geiger Photodiodes ARA Gamma - Ray Counter
Slide 17: Systems
17 Systems HiRIS – High Resolution Imaging System X - ray Image of a 30 Caliber Bullet NYSEARCH Gas Pipeline Probe Fire Scout Field Prototype M aintenance Tool* DCS probe for Clinical Studies Space W eather Monitor *NAVAIR Public Release SPR - 2015 - 1119 Distribution Statement A - Approved for publ
Slide 18: Dynasil Annual Stockholders’ Meeting
Dynasil Annual Stockholders’ Meeting February 2016
Slide 19: About Xcede
5 4 3 2 About Xcede 19 1 Large Market Opportunity Initial cumulative target markets of over $1 billion in mild, moderate and severe bleeding with significant expansion potential Unique Technology Fully bioresorbable , hemostatic patch backed by proprietary technology and extensive IP protection Stro
Slide 20: Experienced Management Team
Experienced Management Team Linda Zuckerman, PhD President and CEO • 2013 – 2015 VP Global Scientific Lead, Hemostasis /Surgery & Preop . Care – The Medicines Company (MDCO) (Secured US approvals for RECOTHROM ® (generated $64.4 million in sales in 2014) and US and EU approvals for Raplixa ® ) • 200
Slide 21: Lead Product: Xcede Hemostatic Patch
Lead Product: Xcede Hemostatic Patch 21 Fully bioresorbable , scalable mesh patch with proprietary adhesive backing that forms the basis of multiple hemostatic products Adjunct to Hemostasis (Mild to Moderate Bleeding) ▪ Liver resection ▪ Soft tissue surgery ▪ Select bone bleeding and spinal bleedin
Slide 22: Competitive Advantages
Competitive Advantages 22 Mechanicals Thrombins + Gelatins “ Flowables ” Fibri n Sealants Other Patches & Pads Xcede Patch Competitive Price X X X High Burst Strength X Fast - Acting X* X* X* X** Resorbable X X X X X Ready - to - use X X X Pliable / Conforms to complex topographies X X X Room Temper
Slide 23: US and EU Markets for the Xcede Patch
US and EU Markets for the Xcede Patch EU Adjunct to Hemostasis Market $537 M $87 M $1.09 Billion $465 M Untapped Severe Bleeding Market 23 US Adjunct to Hemostasis Market
Slide 24: Why Stop at Hemostasis? Xcede’s Portfolio Development
Why Stop at Hemostasis? Xcede’s Portfolio Development 24 Product Indication 2017 2018 2019 2020 2021 Lung Sealing Traumatic Pneumothorax Laparoscopic Adjunct to hemostasis in laparoscopic surgery Vascular Surgery Adjunct to hemostasis for mechanical sealing in vascular surgery Femoral Artery Femoral
Slide 25: Entire Portfolio Backed by Strong IP
Entire Portfolio Backed by Strong IP Issued Patent Number Expiration Tissue Patch - Systems and methods 8,999,376 12/22/2032 Adhesive Compositions & Methods (Allowed) Pending 8/7/2035 Tissue Patch (Allowed) - Tissue Patches, and Associated Kits, and Methods Pending 2/24/2035 Pending Application Numb
Slide 26: New Strategic Partnership Cook Biotech
New Strategic Partnership 26 Cook Biotech 3 Agreements signed in January of 2016: • Patch Development • Manufacture and Supply • Royalty bearing license to our adhesive technology for products outside of Xcede’s field of use
Slide 27: Use of Proceeds
Use of Proceeds 27 Target milestones with funding of additional $7M 1. Completion of tech transfer to Cook 2. Continued hiring of experienced management team 3. Initiation of First - in - human (FIH) safety study 4. Positive safety & efficacy results from FIH Research & Development Clinical Trials G
Slide 28: Investment Outreach and Valuation Sensitivity
Investment Outreach and Valuation Sensitivity 28 Fundraising - Engaged Chardan Capital Markets for Private Equity Round of $3 million - $7 million - Kicked off Roadshow on December 15, 2015 - Active discussion are ongoing - Reviewing strategic alternatives - Targeted closing mid - 2016 Dynasil Owner
Slide 29: Questions
29 Questions
Slide 30: Annual Meeting of Stockholders
Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick Chairman, President and CEO February 26, 2015
Dynasil Corp of America — Shareholder Meeting (February 2016) on 6ix